India’s largest pharmaceutical company steps onto global mergers and acquisitions stage

In April, it was announced that Sun Pharmaceutical Industries, India’s largest pharmaceutical company, had signed to acquire Organon, a global company focused on women’s health. The deal reflects India’s ongoing evolution from a source of growth to a global consolidator.

Interested in learning more about investment for healthtech innovation? Sign up to the HIN Investment Update.

For many years, investment in India’s healthcare and life sciences sectors has centred on its rapidly expanding domestic market, including cost-efficient manufacturing and generics leadership, a clinically equivalent alternatives to branded medicines. This pattern is beginning to change, as leading Indian healthcare companies pursue large-scale international transactions.

One of the defining transactions of 2026 was announced in April, as Sun Pharmaceutical Industries signed to acquire Organon in an all-cash transaction with an enterprise valuation of $11.75 billion. Organon, which spun out of Merck & Co (MSD) in 2021, brings a portfolio of more than 70 products, spanning women’s health, established medicines and biosimilars, which are commercialised across 140 countries.

This landmark acquisition is strategically important for Sun Pharma, as it provides immediate scale in women’s health; access to a global biosimilars platform; and a substantially broader international commercial footprint. Following completion, the combined business is expected to generate approximately $12.4 billion in annual revenue, rank among the world’s top 25 pharmaceutical companies, and become a top three global player in women’s health.

More importantly, the transaction signals a shift in ambition. Rather than relying on organic growth in generics, larger Indian pharmaceutical companies are increasingly looking beyond their home market to acquire differentiated capabilities, established brands and access to global markets.

Beyond headline mergers and acquisitions (M&A), the broader healthcare investment environment remains active. According to Grant Thornton Bharat, India’s pharmaceutical and healthcare sector recorded 78 deals worth $1.9 billion in the first quarter of 2026 alone. Investor interest is focusing on scalable, capability-led businesses, particularly in AI-enabled diagnostics, digital health, preventive care and specialist healthcare services.

As India continues to combine a rare mix of scientific talent, scale and corporate ambition, shifts in investment like the Sun Pharma–Organon deal could see the country evolve from a source of growth to a global consolidator.

Find out more about the acquisition

Subscribe to the HIN Investment Update for key investment news, exclusive insights from the HIN’s investor network, and the latest opportunities and events. Ideal for growing healthtech companies, as well as funders and investors shaping the health innovation ecosystem.